Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Avior Wealth Management LLC

Avior Wealth Management LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,551 shares of the biopharmaceutical company’s stock after acquiring an additional 3,129 shares during the period. Avior Wealth Management LLC’s holdings in Gilead Sciences were worth $1,140,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Concord Asset Management LLC VA raised its holdings in Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 111 shares in the last quarter. TFB Advisors LLC raised its holdings in Gilead Sciences by 1.2% in the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after acquiring an additional 116 shares in the last quarter. Sumitomo Life Insurance Co. raised its holdings in Gilead Sciences by 0.7% in the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after acquiring an additional 117 shares in the last quarter. FDx Advisors Inc. raised its holdings in Gilead Sciences by 2.2% in the third quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock valued at $450,000 after acquiring an additional 117 shares in the last quarter. Finally, Sivia Capital Partners LLC raised its holdings in Gilead Sciences by 3.9% in the third quarter. Sivia Capital Partners LLC now owns 3,249 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 123 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $93.07 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a 50-day moving average of $91.65 and a 200-day moving average of $84.68. The firm has a market cap of $115.99 billion, a price-to-earnings ratio of 1,034.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the firm posted $2.29 EPS. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 456,234 shares of company stock worth $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on GILD shares. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Bank of America reissued a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.